FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:452-455 August 9, 2001 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Albrecht, M. A. PubMed Citation

Combination therapy with three antiretroviral drugs improves the outcome of patients infected with human immunodeficiency virus type 1 (HIV-1) and has led to sustained decreases in AIDS-related morbidity and mortality in North America and Europe.^1,2,3 Long-overdue attention has recently focused on providing this lifesaving therapy to persons with HIV-1 infection in developing countries.⁴ But even under ideal circumstances, current antiretroviral therapy has substantial limitations. Foremost among them are side effects of the medications and incomplete suppression of HIV-1 replication, which allows the emergence of drug-resistant variants of HIV-1.

Antiretroviral therapy is most effective the first time it is prescribed. Suppression . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hammer, S. M., Vaida, F., Bennett, K. K., Holohan, M. K., Sheiner, L., Eron, J. J., Wheat, L. J., Mitsuyasu, R. T., Gulick, R. M., Valentine, F. T., Aberg, J. A., Rogers, M. D., Karol, C. N., Saah, A. J., Lewis, R. H., Bessen, L. J., Brosgart, C., DeGruttola, V., Mellors, J. W., for the AIDS Clinical Trials Group 398 Study Team, (2002). Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial. JAMA 288: 169-180 [Abstract] [Full Text]  
• Manfredi, R., Calza, L., Chiodo, F. (2002). A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. J Antimicrob Chemother 49: 723-729 [Abstract] [Full Text]